GleamWall
中文EN

EOCN EoCene Ltd.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1595353 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026-06-30), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-30.1%
TTM EPS YoY-182.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-68.2%
ROA-55.0%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets30.3%
Debt / equity0.00x
Current ratio4.16x
Interest coverage—

Cash quality & payout

Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026-06-302026-06-302026-03-312026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-312024Q32024-09-30
Income statement
Revenue————————
R&D expense$1.78M—$2.10M$1.09M$1.06M—$1.07M$738,000
SG&A expense$993,000—$946,000$1.01M$1.05M—$572,000$1.27M
Net income-$2.72M-$1.91M-$4.82M-$1.89M-$2.50M-$1.10M-$3.21M-$1.91M
EPS (basic)2.86——0.335.06——2.31
EPS (diluted)2.86——0.335.06——2.31
Weighted avg. shares (diluted)952,168——5.46M493,524——829,500
Balance sheet
Cash & equivalents$2.88M—$3.98M$3.31M$4.96M—$4.65M—
Short-term investments$5.88M—$7.03M$8.18M$8.10M—$7.18M—
Receivables——————$672,000—
Current assets$11.71M—$18.63M$19.72M$21.08M—$16.12M—
PP&E, net$48,000———————
Goodwill$1.76M———————
Total assets$18.28M—$18.63M$21.58M$22.94M—$18.50M—
Current liabilities$2.81M—$2.85M$2.47M$2.42M—$2.17M—
Total liabilities$5.54M—$2.85M$2.47M$2.42M—$2.17M—
Shareholders' equity$12.74M$13.95M$15.78M$19.11M$20.52M$16.88M$16.33M$18.44M
Shares outstanding1.00M—822,6745.48M5.30M—1.66M—
Cash flow statement
Operating cash flow——-$1.95M-$1.94M——-$1.91M-$1.12M
Investing cash flow——$1.43M-$3,000——-$2.45M-$486,000
Financing cash flow——$1.19M$289,000——$448,000—
Depreciation & amortization——————$0$0
Stock-based compensation——$240,000$105,000——$116,000$132,000

Free plan shows the latest 8 periods; Pro shows all 25 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.